Replies to post #551 on Edge Therapeutics fka EDGE

[Smilin_B]

EMAIL from EDGE today:

As you can imagine, we too were quite disappointed with the recent news about the NEWTON 2 study. We certainly appreciate all the support that you and other investors have provided us.

We anticipate in the near term reducing the scope of our operations, including the size of Edge’s workforce, in order to preserve the company’s cash resources. Edge had $88M in cash at December 31, 2017, of which $20M is debt. We have currentlyhalted further clinical development of EG-1962 based on the interim analysis outcome. Next steps for the program, if any, are pending completion of our analysis of the full NEWTON 2 data set. We will work with our Board to evaluate all strategic alternatives in order to maximize shareholder value. The company’s next corporate update will likely be the first quarter conference call in early May.

 

Thank you again.

Greg Gin

[e-mail]